L.J. Altfest & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

L.J. Altfest & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,339	Closed	-$346K	–	275
2022 Q4	$346K	Sell	3,339 -21	-0.6%	-$1.97K	0.06%	197
2022 Q3	$285K	Buy	+3,360	New	+$299K	0.05%	212
2021 Q4	–	Sell	-3,557	Closed	-$275K	–	250
2021 Q3	$275K	Sell	3,557 -1,656	-32%	-$131K	0.06%	219
2021 Q2	$435K	Sell	5,213 -933	-15%	-$74K	0.09%	157
2021 Q1	$464K	Sell	6,146 -496	-7%	-$40.5K	0.11%	149
2020 Q4	$582K	Buy	6,642 +95	+1%	+$7.53K	0.14%	113
2020 Q3	$498K	Buy	6,547 +2,302	+54%	+$233K	0.13%	119
2020 Q2	$524K	Buy	4,245 +1,747	+70%	+$174K	0.15%	104
2020 Q1	$211K	Buy	+2,498	New	+$215K	0.07%	177

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

L.J. Altfest & Co's BMRN Position: Q1 2023 in Review

L.J. Altfest & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 3,339 shares — an estimated $346K sold.

L.J. Altfest & Co first reported a position in BMRN in Q1 2020 and held it in 9 quarters. The position peaked at $582K in Q4 2020. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

L.J. Altfest & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
L.J. Altfest & Co sold 3,339 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $346K.
L.J. Altfest & Co first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 9 quarters.
L.J. Altfest & Co's BioMarin Pharmaceuticals position peaked at $582K in Q4 2020.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on L.J. Altfest & Co's 13F filing for Q1 2023, filed 20 Apr 2023.